This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Abbott's St Jude Buyout to Boost Business, Risks Remain
by Zacks Equity Research
On Mar 31, we updated our research report on medical device major, Abbott Laboratories (ABT).
Community Health Completes Tender Offer for Senior Notes
by Zacks Equity Research
Community Health Systems, Inc. (CYH) recently announced the completion of the previously announced cash tender offer for its outstanding 5.125% Senior Secured Notes, due 2018.
Zacks.com featured highlights: Inogen, Diamondback Energy, Radiant Logistics, Mitek Systems and LPL Financial Holdings
by Zacks Equity Research
Zacks.com featured highlights: Inogen, Diamondback Energy, Radiant Logistics, Mitek Systems and LPL Financial Holdings
Why Is Inogen (INGN) Up 3.9% Since the Last Earnings Report?
by Zacks Equity Research
Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merit Medical (MMSI) Closes 5.2M Follow-On Share Offering
by Zacks Equity Research
Merit Medical Systems, Inc. (MMSI) announced that it has closed its follow-on public offering of 5.2 million shares of common stock at $28.25 per share.
Envision (EVHC) Teams Up with Lyft to Focus on Transportation
by Zacks Equity Research
Envision Healthcare Corporation (EVHC) recently announced that it has teamed up with on-demand transportation service provider Lyft.
Beat Market with 5 Stocks Having Earnings Surprise Potential
by Sweta Killa
Earnings surprise history indicates a company's consistency in beating market estimates.
Genomic Health's GPS Predicts Metastatic Prostate Cancer
by Zacks Equity Research
Genomic Health, Inc. (GHDX), a global cancer company, recently unveiled positive results regarding Oncotype DX Genomic Prostate Score (GPS).
NuVasive (NUVA) Gets FDA 510(k) Clearance for CoRoent System
by Zacks Equity Research
Leading medical device company NuVasive, Inc. (NUVA) recently announced the receipt of U.S. FDA 510(k) clearance for its CoRoent Small Interbody System.
Cerner (CERN) Banks on RCM & PH Platforms, Competition Rife
by Zacks Equity Research
On Mar 29, we issued an updated research report on North Kansas City, MO-based Cerner Corporation (CERN) ??? a leading global provider of healthcare information technology solutions (HCIT).
QIAGEN Offers JAK2 Kit in US, Grows in Molecular Diagnostics
by Zacks Equity Research
QIAGEN N.V. (QGEN) launched ipsogen JAK2 RGQ PCR Kit in the U.S, following the Food and Drug Administration's (FDA) approval.
Strong Buys at New Highs
by David Bartosiak
Dave's Daily Dive and five new strong buys breaking out
Here's Why You Should Steer Clear of Mednax (MD) for Now
by Zacks Equity Research
Over the past 6 six months, shares of Mednax (MD) have gained 4.9%., underperforming the 9.8% increase logged by the Zacks categorized Medical - Hospital industry.
Integra LifeSciences Expands Cadence System Commercially
by Zacks Equity Research
Integra LifeSciences Holdings Corporation (IART), a global medical technology company, recently announced full commercial expansion of its Cadence Total Ankle System.
Intuitive Surgical Hits 52-Week High on Multiple Positives
by Zacks Equity Research
Shares of leading provider of robotic-assisted surgery, Intuitive Surgical, Inc. (ISRG) rallied to a new 52-week high of $770.28 on Mar 28, closing a tad lower at $764.47.
Akers Receives Cholesterol Test Kit Order from First Check
by Zacks Equity Research
Akers Biosciences, Inc. (AKER) announced that it has received an initial order under the distribution agreement for its rapid cholesterol self-test kit.
Renewed Obamacare Repeal Effort Sends Hospital Stocks Down
by Benjamin Rains
Hospital stocks have dipped again amid reports that House Republicans will continue to pursue their health care reform plan in 2017.
Obamacare Holds Ground: 3 Medical Device Stocks to Gain
by Zacks Equity Research
Republican leaders have failed to play their "Trump card" this time, courtesy of the pullback of the Republican healthcare bill, the American Health Care Act (ACHA), which was designed to repeal the Affordable Care Act (ACA) or Obamacare.
Henry Schein (HSIC) Poised on Solid Growth, Risks Remain
by Zacks Equity Research
On Mar 27, we issued an updated research report on Melville, NY-based Henry Schein, Inc. (HSIC).
BioScrip (BIOS) Stock Declines on Dull Q1 EBITDA Outlook
by Zacks Equity Research
Bioscrip, Inc.'s (BIOS) shares witnessed a 2.2% fall in yesterday's trading session, closing at $1.78.
Evolent Health (EVH) Prices 7.5M Follow-On Share Offering
by Zacks Equity Research
Evolent Health, Inc. (EVH) announced the pricing of its follow-on public offering of 7.5 million shares of Class A common stock at $21.25 per share.
LifePoint Grows Inorganically Yet Stock Suffers: Here's Why
by Zacks Equity Research
Despite its efforts to grow inorganically, LifePoint's shares returned 15.2% compared with a 31% gain for the Zacks categorized Medical Hospital industry over the past three years.
DexCom Gains as CMS Announces Criteria for G5 Mobile CGM
by Zacks Equity Research
The Centers for Medicare & Medicaid Services published an article clarifying the criteria for coverage of its DexCom (DXCM) G5 Mobile CGM system for patients with diabetes and on intensive insulin therapy.
Align Partners Zfx GmbH to Expand iTero Scanner Business
by Zacks Equity Research
Align Technology Inc. (ALGN) announced a non-exclusive agreement with digital prosthetic solutions maker, Zfx GmbH on iTero Element intraoral scanners.
VWR Corp Acquires EPL Archives, Improves Customer Service
by Zacks Equity Research
VWR Corporation (VWR) recently acquired the international biorepository services organization, EPL Archives, Inc.